Twenty-six adult patients, median age 36 years (range 21-53) with chronic myeloid leukemia in first chronic phase were allotransplanted between October 1989 and May 1995. The preparative regimen consisted of busulphan 16 mg/kg and cyclophosphamide 200 mg/kg (big BU/CY). Cyclosporin A and methotrexate were used for GVHD prophylaxis. Twenty-two donors were HLAidentical siblings and four donors were mismatched for one antigen of class I. The global incidence of acute GVHD was 50%, that of severe aGVHD (grades 3-4) was 11%; the global incidence of chronic GVHD was 30%. No patients developed veno-occlusive disease of the liver or interstitial pneumonia. Five patients died, one of relapse, four of transplant-related causes, mostly related to aGVHD; thus, the transplant-related mortality was 16%. Twenty-one patients are alive, in remission, with a median follow-up of 55 months (range 24-90); actuarial probability of survival is 78% (CI 64-96). Our study shows that this conditioning regimen is relatively easy to administer and seems to be as effective as, if not superior to, regimens containing TBI, in patients with chronic myeloid leukemia in chronic phase and the transplant-related mortality is not excessive even in older patients. Keywords: CML; alloBMT; BU/CY The prognosis for persons with Ph + chronic myeloid leukemia (CML) has not changed substantially during the past decades when patients were treated with conventional chemotherapy based on busulphan (BU) or hydroxyurea. The results with ␣-interferon seem to be promising but there is not yet an adequate follow-up for patients who receive this form of therapy.
about 50%. [2] [3] [4] [5] [6] [7] [8] [9] However, less known are the results of regimens not containing TBI. The main regimen of this kind was described in 1983 by Santos et al, 10 who employed a combination of BU (16 mg/kg) followed by cyclophosphamide (CY) (200 mg/kg), although in patients with acute myelogenous leukemia. Subsequently, a variation of this conditioning regimen, employing a reduced dose of CY, 120 mg/kg, has been used in CML, 11 and the most recently reported studies have employed this dose of CY (small BU/CY). 12, 13 The main results of these BU-based regimens have been characterized by a rather low incidence of transplant-related mortality (TRM) and relapse. Only one study has reported the original big BU/CY regimen in CML. Galimberti et al 12 in 1994 described a series of patients with CML in CP conditioned with the big BU/CY, who were Ͻ35 years old; the overall survival and relapse-free survival coincided and were 71%; the TRM was 22%. Starting in 1989 we employed the big BU/CY regimen and have transplanted 26 patients with CML in first CP.
All received CsA + MTX as GVHD prophylaxis. Our results, with a median follow-up of all patients of 48 months (range 2-90) and a median follow-up of the live patients of 55 months (range 24-90), indicate a very low incidence of relapse and a TRM of about 16%, with a 5 year DFS of 78% (CI 30-96).
Materials and methods

Patients
Twenty-six consecutive patients with Ph + CML in first CP entered the study, from October 1989 to May 1995. Chronic phase was defined by a finding of less than 10% non-granulated blast cells or less than 20% blast cells and promyelocytes in peripheral blood or bone marrow and by absence of any other extrahematologic involvement. The characteristics of these patients are shown in Table 1 . The median age was 36 years (range 21-53 years). There were 15 males and 11 females. As treatment of their disease, before transplant all patients received hydroxyurea, 5 patients also received BU and 12 received ␣IFN for a median of 13 months (range 8-75). None of them had undergone splenectomy. The mean interval between diagnosis and BMT was 23.5 months (range 8-78): only four patients were transplanted within 1 year from diagnosis; for 5 patients the interval between diagnosis and BMT was Ͼ3 years.
Donors
Twenty-two donors were HLA-identical siblings, MLR negative; four donors were mismatched for one antigen of class I. Median donor age was 38 years (range 23-62 years); there were 13 males and 13 females. The serological status for CMV was as follows: negative donor and recipient one, positive donors and recipients 19, positive donors and negative recipients six.
Preparation
Patients received BU orally at a dose of 4 mg/kg of corrected body weight, in four divided doses, for 4 consecutive days, from days −9 to −6. BU powder was used to fill wafers of the desired weight; these were more palatable and were prepared at the hospital pharmacy. Cyclophosphamide was then administered i.v. over 1 h at a daily dose of 50 mg/kg of corrected body weight for 4 consecutive days from days −5 to −2. The four 1 Ag-mismatched patients also received antithymocyte globulin (ATG; Fresenius, Bad Homburg, Germany) over 5 days before transplant (from days −6 to −2) at a total dose of 13 mg/kg. Bone marrow was the source of stem cells; it was collected from both posterior iliac crests by standard techniques and was infused 24 h after the last dose of CY: it was unmanipulated, except for removal of red cells or plasma according to class of ABO incompatibility. The mean number of infused cells was 2.9 × 10 8 /kg (range 1.89-5.4).
Graft-versus-host disease (GVHD) prophylaxis
All patients received CsA and short course MTX. 13 CsA was administered i.v. from days −1 until +21 or resumption of oral intake. Tapering was done very slowly between the 7th and 12th month. We adapted the dose to maintain CsA blood levels between 100 and 200 ng/ml measured by fluorescent polarized immune assay (FPIA).
14 MTX was administered i.v. at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11, without folinic acid rescue. Clinical acute GVHD was graded according to Glucksberg et al. 15 Chronic GVHD was diagnosed according to the criteria of Shulman et al. 16 
Supportive therapy
All patients were nursed in reverse barrier isolation. Hyperhydration (1500 ml/m 2 dextrose saline/day) and urine alkalinisation with i.v. bicarbonate were given during BU administration. Hydration was increased during CY administration (3000 ml/m 2 ). Mercaptoethane sulphonate (mesna), 60% of the total dose of CY was used as prophylaxis of urothelial toxicity from days −5 to −2. Bladder irrigation with 20 l of dextrose saline over 24 h was employed, beginning in 1990, until 1993, in 19 patients. Antifungal prophylaxis with oral amphotericin B was started from day −10 and all patients received 4-fluorquinolone orally for partial gut decontamination. Acyclovir i.v. at a dose of 10 mg/kg three times a day was given from day −5 before BMT until day +28; it was then administered orally, for 9 months after BMT. Hematopoietic growth factors were not routinely administered. No specific prophylaxis against veno-occlusive disease (VOD) of the liver was employed. All blood products were leukocyte-depleted by filtration and irradiated with 20 Gy. Cotrimoxazole, 800 mg twice weekly post transplant was given as soon as sustained engraftment had occurred until 6 months after BMT, for Pneumocystis carinii prophylaxis.
Diagnosis of VOD and interstitial pneumonia
VOD was diagnosed if jaundice occurred with two of the following signs: painful hepatomegaly, ascites or weight gain (in the absence of other known causes) Ͼ5% of baseline level. 17 Interstitial pneumonia (IP) was diagnosed according to the usual criteria. 18 
Chimerism
Patients were evaluated for chimerism when a cytogenetic marker or blood group difference existed between them and their donor, at the time of cytogenetic analysis or between 6 and 12 months after transplant.
Definition of relapse
Cytogenetic relapse was defined as the reappearance of any Ph chromosome positivity, analyzing at least 25 metaphases, Ͼ3 months after BMT. Cytogenetic relapse was categorized as transient when Ph-positive metaphases cleared from the bone marrow and were undetectable 3 months later. Hematologic relapse was defined as the reappearance of typical blood characteristics.
Patients were studied at 3, 6, 12 months after BMT and then every year, with cytogenetic analysis.
Transplant-related mortality
Transplant-related mortality was defined as any cause of death other than underlying disease. 19 
Statistical analysis
Survival was calculated by the Kaplan-Meier product limit method, 20 from transplant to death or to last follow-up; dis- ease-free survival was calculated from transplant to relapse or death or to last follow-up; transplant-related mortality was calculated from transplant to death for any cause other than leukemia. Thirteen patients developed acute GVHD with a global incidence of 50%. Seven patients developed grade I GVHD, three patients grade II and three patients grade IV (one of them had received a 1 Ag-mismatched transplant). The median day of onset of acute GVHD was +21 (range 8-54 days). Of the three patients with grade IV, two patients died on day +60 and the third died at 6 months because of infection.
Results
All
Eight out of 23 evaluable (survival Ͼ100 days) patients developed chronic GVHD, five of limited grade, with a global incidence of 30%.
Our series included four mismatched patients. Their ages were 23, 36, 46, 47 years, respectively. The intervals between diagnosis and BMT were 14, 33, 47, 78 months, respectively. One patient developed grade IV acute GVHD and died of it. The three others are alive and well, with no evidence of chronic GVHD.
Three patients died of acute GVHD, one patient of fungal pneumonia and one patient died before relapse. The transplant-related mortality was 16% (see Figure 1) ; the causes of death are reported in Table 2 .
The median follow-up of the whole series is 48 months Figure 1 . Four patients were allotransplanted within 1 year of diagnosis and they are all alive. The actuarial survival of the 17 patients transplanted between 1 and 3 years from diagnosis is 76% (Cl 56-97) and that of the five patients transplanted Ͼ3 years from diagnosis is 80% (Cl 45-100).
Actuarial overall survival at 5 years is 78% (see Figure 2 ). There was only one relapse (UPN 121). The relapse was hematologic and it occurred 29 months after BMT. After six months on ␣IFN therapy the patient received a second allogeneic BMT from the original donor. The conditioning regimen was CY/TBI but she also relapsed after this second BMT and died of fungal pneumonia, with active leukemia.
Nineteen patients were evaluated for chimerism: 14 because of donor sex mismatch and five because of blood group differences. In all cases complete donor chimerism was demonstrated.
One patient (UPN 122) showed a transient cytogenetic relapse: one Ph + metaphase out of 50 was detected 27 months after BMT. He received ␣IFN, at a dose of 3 MU 3 days a week, for 3 months and the karyotype was normal at the next analysis, 3 months later, and has remained so.
Discussion
Allogeneic BMT is the only curative therapy for CML. After a conditioning regimen consisting of CY/TBI, in the majority of published series, a DFS ranging from 40 to 70% has been repeatedly reported 2-9 at 3-5 years. An alternative regimen was proposed by Santos et al 10 for acute leukemias, which was based on busulphan (16 mg/kg) and cyclophosphamide (200 mg/kg). However, nearly all studies in CML employed BU/CY2 (with a reduced dose of CY) and obtained good results in terms of overall survival, relapserisk and DFS. Biggs et al 11 reported a series of patients conditioned with BU/CY2 and the median age was 35 years; the DFS was 58%. In 1995 the French Society of Bone Marrow Graft (SFGM) 21 described two groups of patients randomly assigned to receive CY/TBI or BU/CY2. The median age of those patients was 36 years. The overall survival was 60.6% and the DFS was 55% in the BU/CY2 group. The relapse risk was 4.4%. Thus, these findings do not show an increased incidence of transplant-related toxicity and mortality, incidence or severity of GVHD, which have been reported in some studies after allogeneic BMT for acute leukemia, employing the BU/CY2 regimen.
22,23
However, we have previously demonstrated, in a population of adults with a variety of hematological malignancies -acute leukemias, chronic myeloid leukemias, multiple myeloma -that the toxicity of the big BU/CY regimen was not elevated. 24 The use of methotrexate, in addition to CsA, is probably important in preventing GVHD and its associated complications: in our study, the incidence of grades III-IV GVHD was 11%, similar to the best results reported in the literature 25 and the incidence of chronic GVHD has been 30%, which is also on the low side of what is commonly observed. On the other hand, the superiority of the CsA/MTX combination in allogeneic BMT for CML has also recently been confirmed. 26 Only one study, by Galimberti et al, 12 used the big BU/CY regimen, but only for patients Ͻ35 years old, and they reported an overall survival and a TRM of 78 and 22%, respectively, compared with 63 and 38% in patients aged Ͼ35 years conditioned with BU/CY2. This paper describes a series of 26 consecutive patients allotransplanted for CML in first CP. They all received unmanipulated bone marrow and the preparative regimen consisted of big BU/CY. Although the mean age was 36 years, there were nine patients aged Ͼ40 years and one patient Ͼ50 years old. The conditioning regimen for these 10 patients was not modified and no significantly different outcomes have been identified, with respect to regimen-related toxicity, rate of engraftment, GVHD incidence, compared to the younger ones. The overall survival and DFS coincided and were 78%; the TRM was 16%. These figures are similar to those described by Clift et al 27 in 1994 in a group of patients conditioned with BU/CY with a mean age of 38 years, but the regimen used was the BU/CY2. An important issue, in CML, is the diagnosis-BMT interval which seems to significantly influence the transplant, and an interval Ͻ1 year is described to be one of the best prognostic factors. 4, 27 A report by the IBMTR 28 analyzed a large series of patients and the different outcome of early transplants was not demonstrated, but a subsequent study 29 showed an advantage for patients transplanted Ͻ1 year from diagnosis. However, both this study and a previous one by Biggs et al 11 showed that the correlation between a longer diagnosis-BMT interval and worse outcome applied mainly to patients treated with busulphan instead of hydroxyurea. It is likely that previous exposure to busulphan could effect increased damage to various organs, especially lungs, rendering them more susceptible to additional damage from the conditioning regimen. In our report four patients received their transplant within 1 year from diagnosis and only five patients received busulphan prior to transplant: the numbers are too low to draw any conclusions but the fact remains that, with a median interval diagnosis-BMT of 23 months, DFS was good. Our series includes four mismatched patients. Despite three patients older than 35 years and a diagnosis-BMT interval Ͼ33 months the outcome of transplant for these four patients was not different from that observed in the fully matched transplants. One patient had grade IV acute GVHD and died of it. The three others are alive and well with no evidence of cGVHD. These results, although observed in a very small group of patients, confirm that for patients with a one Ag-mismatched donor the results of transplant are similar to those seen with a fully HLA-identical donor, as already demonstrated by the Seattle group, 30 also with an important conditioning regimen as the big BU/CY and with CsA + MTX as GVHD prophylaxis.
The relapse rate in this group has been low. One patient showed a transient cytogenetic relapse (1/50 positive metaphase); he was treated with ␣IFN for 3 months and the karyotype was normal at the next examination. It is impossible to say if this was due to the therapeutic intervention or was natural evolution, as it is rather commonly observed after unmanipulated transplant in chronic phase CML. 31 Such incidence of relapse is similar to that reported by other groups who used the same conditioning regimen. [11] [12] [13] Our study was based on a small series of patients and perhaps its results may not be reproduced on a larger scale in many different centers. Despite this limitation, we have shown that big BU/CY is relatively easy to administer and seems to be, at least, as effective as, if not superior to, CY/TBI in patients with CML in CP. The regimen-related toxicity and TRM were not excessive even in older patients, and a long-term DFS in the range of 75% can be reasonably expected. Considering these results, the testing of new conditioning regimens or alternative sources of stem cells for improved antileukemic efficacy will be very difficult, while a further reduction of TRM should be the target of future studies of allogeneic BMT in CML.
